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OBJECTIVES: Brain metastases due to breast cancer are increasing, and the prognosis is poor. Lack of effective
therapy is attributed to heterogeneity of breast cancers and their resulting metastases, as well as impermeability
of the blood–brain barrier (BBB), which hinders delivery of therapeutics to the brain. This work investigates three
experimental models of HER2+ breast cancer brain metastasis to better understand the inherent heterogeneity of
the disease. We use magnetic resonance imaging (MRI) to quantify brain metastatic growth and explore its
relationship with BBB permeability. DESIGN: Brain metastases due to breast cancer cells (SUM190-BR3, JIMT-1-
BR3, or MDA-MB-231-BR-HER2) were imaged at 3 T using balanced steady-state free precession and contrast-
enhanced T1-weighted spin echo sequences. The histology and immunohistochemistry corresponding to MRI
were also analyzed. RESULTS: There were differences in metastatic tumor appearance by MRI, histology, and
immunohistochemistry (Ki67, CD31, CD105) across the three models. The mean volume of an MDA-MB-231-BR-
HER2 tumor was significantly larger compared to other models (F2,12 = 5.845, P b .05); interestingly, this model
also had a significantly higher proportion of Gd-impermeable tumors (F2,12 = 22.18, P b .0001). Ki67 staining
indicated that Gd-impermeable tumors had significantly more proliferative nuclei compared to Gd-permeable
tumors (t[24] = 2.389, P b .05) in the MDA-MB-231-BR-HER2 model. CD31 and CD105 staining suggested no
difference in new vasculature patterns between permeable and impermeable tumors in any model. CONCLUSION:
Significant heterogeneity is present in these models of brain metastases from HER2+ breast cancer.
Understanding this heterogeneity, especially as it relates to BBB permeability, is important for improvement in
brain metastasis detection and treatment delivery.
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Breast cancer will affect approximately one in eight American women
[1]. It is the most commonly diagnosed cancer in women and is the
second leading cause of cancer death in American women [1]. The
major challenge of this disease is its propensity to metastasize to distant
sites such as bone, liver, lung, and brain [2]. The relative rate of breast
cancer brainmetastasis is extremely high, second only to lung cancer [3].
Breast cancer is a complex and heterogeneous disease and is
classified into at least four molecular subtypes with different
prognostic significance; further classification exists by histological
type and grade [2,4,5]. No single subgroup is biologicallyhomogeneous. The HER2 subtype—estrogen receptor negative
(ER−), progesterone receptor negative (PR−), human epidermal
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concern because it accounts for 10% to 15% of breast cancers and
develops brain metastases at a significantly higher rate compared to
other breast cancer subtypes [2,7].
Brain metastases that form from breast cancers are also complex
and heterogeneous. These can manifest in three clinically distinct
situations: multiple brain metastases (78%), solitary brain metastasis
(14%), or leptomeningeal metastasis (8%) [8]. Each manifestation
dictates a different course of treatment; however, responses to therapy
vary among metastases. Some metastases will not respond to therapy,
whereas others will appear to initially respond but develop resistance
during treatment or will cause recurrence at a later time. This
heterogeneity in tumor response complicates clinical management
and contributes to the poor prognosis for this disease.
Clinical data suggest that HER2 overexpression is present in as many
as 53% of breast cancer brain metastasis cases [7]. Median survival from
diagnosis of HER2+ brain metastases to death is 4 to 6months, and less
than 20% of patients can expect to live 1 year [9]. Treatment for
HER2+ metastatic breast cancer includes anti-HER2 therapy such as
trastuzumab (Herceptin). Despite improvement in both disease-free
and overall survival [10], central nervous system metastases develop in
31% to 48% of patients on trastuzumab [11–14]; and 33% to 50% of
those are responding to therapy or have stable disease at other sites when
diagnosed with central nervous system involvement [11,14]. This
suggests that the brain offers a sanctuary site where metastases can
persist, unaffected by therapy.
The poor prognosis for brain metastases has been largely attributed
to obstacles created by the blood–brain barrier (BBB). Under normal
conditions, the BBB acts to protect the brain by tightly regulating the
diffusion of substrates from the blood into the brain parenchyma
[15]; however, this also causes systemic therapies to be excluded from
the brain. For example, chemo- and targeted therapies, such as
doxorubicin and trastuzumab, which are highly successful at treating
HER2+metastases in other areas of the body, are ineffective for brain
metastases [14,16] presumably because they are unable to cross the
intact BBB.
Studying brain metastatic breast cancer is challenging because there
are few experimental animal models [17–20]. The MDA-MB-231-BR
cell line has been the most widely used to study brain metastasis from
breast cancer [18,21–29]. Work performed in the Steeg laboratory has
shown that this preclinical model shares many characteristics of
human brain metastases [22]. The MDA-MB-231-BR cell line has
also been transduced with HER2 cDNA (resulting in the
MDA-MB-231-BR-HER2 cell line), and significant heterogeneity in
the permeability of the BBB associated with these brain metastases was
demonstrated by Lockman et al. [30] using dextran perfusion and
ex vivo fluorescence microscopy.
Imaging is increasingly being used to study models of brain
metastasis. Magnetic resonance imaging (MRI) allows for noninvasive,
three-dimensional (3D), longitudinal studies at very high spatial
resolution; and a wide range of contrast mechanisms are possible.
Contrast-enhanced T1-weighted (T1w) MRI, which relies on tumor
detection by diffusion of gadolinium-DTPA (Gd) across an impaired
BBB in the local region of a tumor, is widely regarded as the most
accurate method for clinical brain tumor detection. A previous imaging
study performed in our laboratory showed that not all 231BR brain
metastases were detectable after Gd-enhanced MRI and that the BBB
permeability changed over time as brain metastases developed [24].
These findings suggest that brain metastases that are not permeable toGd may go undetected by conventional MRI. In addition, heteroge-
neity in BBB permeability between metastases also means that
therapeutic access to individual brain metastases varies [28,30,31].
In this study, we explore the relationship between the growth of brain
metastases and their permeability status in three HER2+ human brain
metastatic breast cancer cell lines, two of which are naturally
HER2-expressing cell lines that have been recently developed. We
present quantification of metastasis volume in the whole mouse brain
using high-resolution 3D MRI as well as an assessment of the integrity
of the BBB associated with each tumor (blood–tumor barrier, BTB).
Correlative histology and immunohistochemistry provide image
validation and further characterization of each cell line.
Methods
Cell Culture
The following three HER2+ human brain metastatic breast cancer
cell lines were used: (1) MDA-MB-231-BR-HER2 [19], (2)
JIMT-1-BR3 [32], and (3) SUM190-BR3. The MDA-MB-231-BR-
HER2 cell line is derived from the breast carcinoma parental line,
MDA-MB-231, and transfected with HER2 [19]; the other two cell
lines were derived from their parental lines—JIMT-1 [20] and
SUM190 [33], respectively—and are naturally HER2+. All three cell
lines were developed in the laboratory of Dr Patricia Steeg at the
National Cancer Institute (Bethesda, MA). For MDA-MB-231-BR-
HER2 and JIMT-1-BR3, cells were maintained in Dulbecco’s
modified Eagle’s medium with 10% fetal bovine serum.
MDA-MB-231-BR-HER2 media also contained penicillin and
streptomycin; the JIMT-1-BR3 media contained 2 mM glutamine.
SUM190-BR3 cells were grown in serum-free Ham F-12 medium
supplemented with insulin and hydrocortisone. All cell lines were
maintained at 37°C and 5%CO2. Cell viability was calculated by the
trypan blue exclusion assay.
Cell Labeling
For a subset of in vivo experiments, cells were labeled with
micron-sized iron oxide particles (0.9 μm MPIO, Bangs Laboratory,
Fishers, IN) for cell tracking by MRI as previously described [21].
Labeling was achieved by coincubating 2 × 106 seeded cells withMPIO
at a concentration of 25 μg Fe/mL for 24 hours in a T75-cm2 flask. The
cells were harvested and thoroughly washed three times with Hanks
balanced salt solution to remove unincorporated MPIO before cell
injection. Perl Prussian Blue (PPB)–stained cytospin slides were
analyzed to determine labeling efficiency; this was calculated in ImageJ
software (Open-source, NIH, Bethesda, MD) as the ratio of
PPB-positive cells to the total number of cells in five random fields of
view at 40× magnification using a Zeiss AXIO Imager A1 Microscope.
Iron-labeled cells create regions of signal void on MR im-
ages [21,23] and allow for the confirmation of successful cell
injections and arrest of cancer cells in the brain; lack of signal voids
results in exclusion from further study.
Animal Preparation
Female nude mice (nu/nu, aged 6-8 weeks, from Charles River
Laboratories, Wilmington, MA) were housed in a pathogen-free
barrier facility, and all experiments were approved by the Animal Use
Subcommittee of the University Council on Animal Care at the
University of Western Ontario. Cells suspended in 0.1 mL of Hanks
balanced salt solution were delivered to female nude mice,
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to the beating left ventricle of the mouse heart.
The three brain metastatic breast cancer models were injected
intracardially into mice. The first group (n = 5) was injected with
100,000 MDA-MB-231-BR-HER2 cells per mouse; another group
of mice (n = 6) was injected with 175,000 JIMT-1-BR3 cells; the final
group (n = 4) was injected with 500,000 SUM190-BR3 cells. The
number of injected cells was selected based on in vivo tumorgenic
potential determined from previous studies [28].
Experimental End Point
Mice were scanned using MRI at the experimental end point and
then euthanized by an overdose injection of pentobarbital (Euthanyl).
The end point was determined by the onset of neurological
symptoms, unacceptable weight loss and body condition, or
hind-limb paralysis. Different degrees of in vivo tumor growth and
aggressiveness caused the end point to be reached at different times for
each model; this is further discussed in our results. The end points
were day 28 for JIMT1-BR3, day 36 for MDA-MB-231-BR-HER2,
and day 64 for SUM190-BR3.
Magnetic Resonance Imaging
All images were acquired on a 3.0-T GE Excite MR750 clinical
scanner (General Electric, Mississauga, Canada) using a custom-built
insertable gradient coil (inner diameter = 17.5 cm, gradient strength =
500 mT/m, and peak slew rate = 3000 T/[m s]) and a custom
solenoidal mouse head radiofrequency coil (inner diameter = 1.5 cm).
Mice were anesthetized (1.5% isoflurane in oxygen), and temperature
was maintained using warm saline bags during the scans. In vivoMRI
was acquired using two pulse sequences: a 3D balanced steady-state
free precession (bSSFP) scan and a two-dimensional post-gadolinium
T1-weighted spin echo (T1wSE) scan.
The bSSFP sequence was used to detect signal voids post–cell
injection on day 0 and to quantify metastases numbers and volumes
in the whole mouse brain. The parameters for the bSSFP scans were
as follows: resolution = 100 × 100 × 200 μm, repetition time = 8 or
10 milliseconds, echo time = 4 or 5 milliseconds, flip angle = 35°,
signal averages = 2, radiofrequency phase cycles = 8, scan time = 28 or
36 minutes. The T1wSE was acquired approximately 40 minutes
after the intraperitoneal administration of 0.2 mL of gadopentetate
dimeglumine (Magnevist, Schering, US; 0.5 mmol/mL) and used to
assess the BTB associated with individual tumors. The parameters for
these scans were as follows: resolution = 156 × 156 × 400 μm,
repetition time = 600 milliseconds, echo time = 20 milliseconds,
signal averages = 8, scan time = 20 minutes. Zero filling interpolation
was applied to all images.
Histology and Immunohistochemistry
At respective end points, all mice were sacrificed by pentobarbital
overdose and perfused with saline and subsequently with 4%
paraformaldehyde or 4% formalin. Brains were excised and placed
in paraformaldehyde for at least another 24 hours. Fixed brains were
processed, paraffin embedded, and serially cut into 5-μm sections.
Tissue sections were deparaffinized, rehydrated, and either histolog-
ically stained with hematoxylin and eosin (H&E) or stained for
CD31, CD105, or Ki67 by immunohistochemistry. Heat-mediated
antigen retrieval with citrate buffer pH 6 was performed for sections
that were to be stained for CD31 or Ki67. All tissue sections were
blocked with Dako protein block, serum free (Dako Canada, Inc,Burlington, ON, Canada); and the following rabbit polyclonal
antibodies were used: anti-CD31 (1:50, ab28364, Abcam Inc,
Toronto, ON, Canada), anti-CD105 (1:1000, ab107595, Abcam
Inc), and anti-Ki67 (1:100, ab833, Abcam Inc). Dako LSAB2
system-HRP (Dako Canada Inc) and Vector DAB peroxidase
substrate kit (Vector Laboratories, Burlingame, CA) were used
according to manufacturers’ instructions to detect positive staining.
All stained sections were counterstained with hematoxylin before
dehydration and mounting. All staining was imaged on an Axio
Imager A1 microscope (Zeiss CANADA, Toronto, ON, Canada)
with a Retiga EXi (QImaging Scientific Research Cameras, Surrey,
BC, Canada) digital camera.
Data Analysis
Images were analyzed using open-source OsiriX image software,
version 3.9.2. Qualitative analysis of signal voids on day 0 confirmed
mice with successful iron-labeled cell injections; lack of signal voids
excluded mice from further study. Brain metastases were counted
manually. 3D tumor volumes were reconstructed using the OsiriX
volume algorithm from the manual segmentation of a region of
interest around each tumor boundary in every bSSFP image slice for
each mouse. Comparison of corresponding bSSFP and T1wSE
images was used to qualitatively assess BTB permeability to Gd—if
metastases were detected on the T1wSE, these were classified as “Gd
permeable”; in contrast, if they were detected on the bSSFP but not in
the corresponding T1wSE, these were deemed “Gd impermeable.” If
corresponding images were not available, permeability status was not
decided. The “Gd-permeable fraction” was determined as the
percentage of Gd-permeable metastases in relation to the total number
of metastases in the whole brain at a specific time point. To evaluate the
proliferative index of Gd-permeable and Gd-impermeable tumors,
Ki67-stained tissue sections were matched to MRI data and imaged
at 40× magnification; all nuclei within a random field of view in
the tumor were manually counted. The proliferative index was
calculated as the percentage of Ki67-positively stained nuclei among
all MDA-MB-231-BR-HER2 cancer cells. All values are presented
graphically as mean ± SE. Statistical analysis was performed using
unpaired t tests, or a one-way analysis of variance followed by Tukey
honestly significant difference tests on GraphPad Prism version 6
software (GraphPad, San Diego, CA).
Results
Representative images of brain metastases from each group are shown
in Figure 1. Contrast in bSSFP images is related to the ratio of spin–
spin to spin–lattice relaxations (T2/T1); in general, metastases appear
hyperintense compared to brain parenchyma because of relatively
higher fluid content and therefore a longer T2 and T2/T1 ratio.
The three models of HER2+ breast cancer brain metastasis each had
a different appearance by MRI as well as in histology and
immunohistochemistry. The SUM190-BR3 tumors were hyperintense
with a hypointense core in bSSFP images (Figure 1A); this appearance
was reflected in the corresponding H&E- and Ki67-stained tissue
sections where a necrotic core was evident (Figure 1D) and
proliferation was evident around the outer edge (Figure 1G). The
JIMT-1-BR3 tumors also appeared hyperintense in bSSFP images
(Figure 1B), and tissue staining showed tumors with dense clusters of
proliferative nuclei (Figure 1E and H). The MDA-MB-231-BR-
HER2 tumors appeared the brightest in bSSFP images (Figure 1C).
In H&E-stained sections, they present as small, dense clusters of cell
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Figure 1. Representative images showing metastases resulting from SUM190-BR3, JIMT-1-BR3, or MDA-MB-231-BR-HER2 human brain
metastatic breast cancer. (A-C) bSSFP images show metastasis burden (hyperintensities); (D-F) correlative H&E-stained sections of the
area indicated by boxes show morphology of tumors in each model; (G-I) Ki67 staining indicates proliferative nuclei in brown. The region
of signal void in the center of the SUM190-BR3 tumor (A) relates to the necrotic core seen in histology (D). JIMT-1-BR3 tumors are
hyperintense in bSSFP (B) and grow as dense and proliferative nuclei clusters (E, H). 231-BR-HER2 tumors are the most hyperintense in
bSSFP (C) and present as clusters of highly proliferative cell nuclei within pockets of edema in H&E (1, I).
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staining indicated that these tumors were highly proliferative
(Figure 1I).
The 3D high-resolution nature of MRI allowed us to quantify
metastasis volume and permeability in the whole mouse brain for each
animal in all three models. We evaluated 198 tumors at experimental
end point across the three models. Tumor incidence and total tumor
burden are shown in Table 1. The SUM190-BR3 model grew few
tumors, and the total tumor volume per brain was relatively low
despite having the most cells injected. The MDA-MB-231-BR-
HER2 model was injected with the least cells, yet grew the mostTable 1. Tumor Incidence and Burden at End Point for Each Brain Metastasis Model
SUM190-BR3 JIMT-1-BR3
500,000 Cells Injected 175,000 Cells Injected
Mouse ID # of Tumors Total Tumor Volume (mm3) Mouse ID # of Tumors
1 1 0.0913 9 28
7 1 0.1697 10 26
8 2 0.6510 12 20
19 1 0.1665 13 5
15 8
17 4
Mean 1.25 0.2696 Mean 15.17
SD ±0.50 0.2568 SD ±10.82
Number of tumors and total tumor volume are shown for each mouse, as well as average values and stand
MDA-MB-231-BR-HER2 mice have the largest, in terms of both number of tumors and total tumor votumors and had the highest total tumor volume. The study end point
was decided when mice displayed clinical symptoms of the disease and
deteriorating health. The time to end point was different for each
model: day 28 for JIMT-1-BR3, day 36 for MDA-MB-231-BR-
HER2, and day 64 for SUM190-BR3. The mean volume of each
tumor was calculated at these times for all mice in each of the three
models (Figure 2). The average volume of a tumor was significantly
different between models (F2,12 = 5.845, P b .05); but interestingly, a
longer experiment did not mean larger tumors. Post hoc Tukey tests
showed that MDA-MB-231-BR-HER2 tumors were significantly
larger in size compared to JIMT-1-BR3 or SUM190-BR3 tumors231-BR-HER2
100,000 Cells Injected
Total Tumor Volume (mm3) Mouse ID # of Tumors Total Tumor Volume (mm3)
5.3570 1 9 1.6861
7.5645 2 11 10.7690
2.8284 3 54 30.9075
1.4802 4 21 7.2567
1.0904 5 7 4.6846
0.6696
3.1650 Mean 20.40 11.06
2.7440 SD ±19.54 11.59
ard deviations within each model. Overall, SUM190-BR3 mice have the smallest tumor burden, and
lume.
SUM190-BR3 JIMT-1-BR3 231-BR-HER2
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Figure 3. Quantification of the mean percentage of Gd-permeable
(black) and Gd-permeable (white) tumors (±SEM). The percentage
of Gd-permeable or Gd-impermeable tumors was significantly
different between groups (F2,12 = 22.18, P b .0001). All
SUM190-BR3 and most JIMT-1-BR3 tumors were Gd permeable,
whereas only 63.6% of MDA-MB-231-BR-HER2 tumors display
BTB permeability to Gd. Post hoc Tukey tests showed that the
MDA-MB-231-BR-HER2 had a significantly different proportion of
Gd-permeable and Gd-impermeable tumors compared to the
JIMT-1-BR3 or SUM190-BR3 models. No other significant differ-
ences in permeability were observed.
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significant difference in tumor volume was observed between
JIMT-1-BR3 and SUM190-BR3 models, yet the SUM190-BR3
model grew for more than twice as long before the mice were noted to
have neurological symptoms.
The tumor permeability status for the three models is shown in
Figure 3. A significant difference was observed in the percentage of
Gd-permeable or Gd-impermeable tumors between models (F2,12 =
22.18, P b .0001). Post hoc Tukey tests showed the
MDA-MB-231-BR-HER2 had a significantly different proportion
of Gd-permeable and Gd-impermeable tumors compared to the
JIMT-1-BR3 or SUM190-BR3 models. All of the SUM-190-BR3
tumors and most JIMT-1-BR3 tumors were Gd permeable, whereas
only 63.6% of the MDA-MB-231-BR-HER2 tumors displayed BTB
permeability to Gd. T1w SE post-Gd MR failed to detect 36.4% of
MDA-MB-231-BR-HER2 metastases that were visible in bSSFP
images. No other significant differences within or between groups
were observed.
Figure 4 shows representative bSSFP and T1w post-Gd images for
a mouse with MDA-MB-231-BR-HER2 brain metastases. Three
metastases were evident in the bSSFP image, yet only two of these
were detectable in the T1wSE post-Gd. This suggested that the BTB
associated with the third metastasis was intact.
Immunohistochemistry was performed and evaluated, including
CD31, CD105, and Ki67 stains, in an effort to understand factors that
might relate to differences between Gd-permeable and Gd-impermeable
tumors. Individual tumors in whole brain sections were identified as
either Gd permeable or Gd impermeable by comparing to MRI. For
this analysis, Gd-impermeable tumors were assessed only from the
MDA-MB-231-BR-HER2 model because of their low prevalence in
the other models. Ki67 is a marker for proliferative nuclei and was used
to calculate the mean proliferative index for Gd-permeable and
Gd-impermeable brain metastases in the MDA-MB-231-BR-HER2
model. The proliferative index was determined as the percentage of
positively stained nuclei among MDA-MB-231-BR-HER2 cells. TheSUM190-BR3 JIMT-1-BR3 231-BR-HER2
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Figure 2. Quantification of mean volume per tumor (±SEM) at end
point in SUM190-BR3, JIMT-1-BR3, and MDA-MB-231-BR-HER2
models. The average volume of a tumor was significantly different
between groups (F2,12 = 5.845, P b .05), and MDA-MB-231-BR-
HER2 tumors were significantly larger in size compared to
JIMT-1-BR3 or SUM190-BR3 tumors. No other significant differences
were observed.proliferative index for Gd-impermeable tumors was significantly higher
than for Gd-permeable tumors (t[24] = 2.389, P b .05) (Figure 5).
CD31 is a marker for endothelial cells, and CD105 marks proliferative
endothelial cells. Together, these stains visualize vasculature patterns
and can indicate where new vessels are being formed. This staining was
only assessed qualitatively, and it is interesting to note the different
staining patterns across the three models. In the SUM190-BR3 model,
CD31 staining was strongly localized to the outer edge of the tumor
rim, whereas CD105 staining was strongest on the inner edge of the
tumor rim. This indicated the presence of vasculature around the tumor
and new vasculature development inside, near the tumor core. The
JIMT-1-BR3 and MDA-MB-231-BR-HER2 models had more similar
patterns of CD31 and CD105 staining; the JIMT-1-BR3 model had
existing and new vasculature dispersed throughout the tumor space,
whereas in MDA-MB-231-BR-HER2 tumors, this appeared to be
associated near areas of edema. Despite variance in vasculature patterns
across the three models, no differences were observed between
Gd-permeable and Gd-impermeable tumors (Figure 6).
Discussion
In vivo MRI is a valuable tool for preclinical investigation of brain
metastatic breast cancer and associated tumor permeability. In the current
work, we used MRI to compare HER2+ brain metastases from the
following three human breast cancer cell lines: (1) MDA-MB-231-BR-
HER2 [19], (2) JIMT-1-BR3 [32], and (3) SUM190-BR3. We show
that there are differences in MRI appearance and permeability to Gd in
three different types of HER2+ brain metastases. Furthermore, these
models exhibit the significant disease heterogeneity seen in the clinic; this
12
3
bSSFP T1w SE post-Gd
Figure 4. In vivo visualization of heterogeneous BTB permeability in the same animal. Axial MR images of the mouse brain; tumor burden is
shown in the bSSFP image (left), and BTB permeability associated with the tumors is indicated in the T1w SE post-Gd (right). Three tumors are
visualized in the bSSFP image, yet only two are detectable in the T1w SE post-Gd. This suggests that Gd cannot cross the BTB associated with
tumor 3 and demonstrates the difference in tumor detection using contrast-enhanced MRI compared to the bSSFP sequence.
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and average size of a tumor in each of these models.
Our Gd-permeability analysis suggests that in vivo tumor permeability
to Gd cannot be explained by lesion size, aggressiveness, or growth
duration. Permeability to Gd indicates a disruption in the BBB, or BTB,
when assessing brain tumors; this is important to understand because BBB
disruption affects our ability to detect and treat brain metastases.
Interestingly, models with smaller tumors—SUM190-BR3 and
JIMT-1-BR3—had significantly higher proportions of Gd-permeable
tumors than the MDA-MB-231-BR-HER2 model, which had many
Gd-impermeable metastases despite formingmuch larger metastases more
quickly than the other models. Moreover, qualitative analysis of staining
for endothelial cells (CD31) and proliferative endothelial cells (CD105)
shows different vasculature patterns across different models of HER2+
brain metastatic breast cancer but suggests no difference in development
of new vasculature amongGd-permeable compared to Gd-impermeable
tumors. This contradicts the dogma that large tumors have more
neovasculature and are more “leaky” [24,34–36]. In addition to size,
tumor aggressiveness does not explain permeability. Indeed, Gd-Gd-permeable Gd-impermeable
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Figure 5. The mean proliferation index (±SD) for Gd-permeable
and Gd-impermeable brain metastases in the MDA-MB-231-BR-
HER2 model. This quantifies tumor proliferation by Ki67 staining
and indicates that there is significantly more proliferative nuclei in
Gd-impermeable compared to Gd-permeable brain metastases
(t[24] = 2.389, P b .05).impermeable tumors in theMDA-MB-231-BR-HER2model exhibited
a significantly higher proliferative index than Gd-permeable tumors.
Our results align with preclinical studies by Lockman et al. [30]
and Percy et al. [24] who have also demonstrated heterogeneity in the
permeability status associated with brain metastases. Varying levels of
passive permeability to Texas Red Dextran (3 kDa) or 14C-AIB (103
Da) were detected in MDA-MB-231-BR-HER2 metastases using
ex vivo fluorescence microscopy or autoradiography, and it was found
that tumor permeability was not correlated with tumor size; in
addition, they suggest that it is also unrelated to morphology or
vascular density [30]. Percy et al. [24] previously used the same
in vivo MRI strategy used in our study and found that Gd-permeable
tumors were significantly larger than Gd-impermeable tumors in the
MDA-MB-231-BR model; however, size alone was not sufficient to
predict permeability. Our work supplements these findings and
further illustrates that tumor size and permeability are not directly
related because models with smaller tumor size had higher
proportions of Gd-permeable metastases. We demonstrate that
tumor permeability is not the same in all models of HER2+ brain
metastatic breast cancer.
The difference in permeability status across and within the models
raises two important clinical implications. Firstly, systemic therapies
may be ineffective because they rely on diffusion of a therapeutic
across an impaired BBB for delivery to metastases. Trastuzumab is
part of the standard treatment for HER2+ metastatic breast cancer;
however, this molecule does not adequately cross the BBB [37] and is
ineffective for brain metastatic breast cancer [11,12]. Interestingly,
our study shows almost all SUM190-BR3 and JIMT-1-BR3 tumors
are permeable to Gd. This molecule is much smaller (590 Da) than
trastuzumab (145 kDa) and therefore may cross the BBB where size
restrictions would exclude trastuzumab. Secondly, and perhaps more
importantly, the population of potentially unresponsive metastases,
due to limited drug uptake, are also not likely to be detected by
current Gd-enhanced imaging strategies.
Importantly, it is possible for brain metastases to develop while
maintaining an intact BBB. This may happen when tumors co-opt
the pre-existing rich vasculature of the brain and develop alongside
pre-existing microvessels [41–43]. In this situation, a large brain
metastasis can develop with an intact BTB because the tumor grows
around a preformed and properly constructed blood vessel. These
tumors are radiographically invisible by Gd-enhanced MRI [41]
because Gd does not extravasate from the intact blood vessel;
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Figure 6. Representative images of CD31 (top) and CD105 (bottom) staining in SUM190-BR3, JIMT-1-BR3, and MDA-MB-231-BR-HER2
models. Staining patterns were qualitatively assessed for the distribution of endothelial cells and proliferative endothelial cells in tumor
regions. Different staining patterns are evident betweenmodels; however, there is no obvious difference in the staining patterns between
Gd-permeable and Gd-impermeable metastases within the MDA-MB-231-BR-HER2 model.
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sequence is advantageous to detect “Gd-impermeable” tumors
because it offers high spatial resolution and contrast is related to
the ratio of spin–spin to spin–lattice relaxations (T2/T1)—rather
than extravasation of a contrast agent. This allows for the visualization
of all brain metastases—regardless of the degree of BBB permeability.
The bSSFP pulse sequence is available on clinical MRI systems but
has been predominantly used for cardiac applications [38]. Further
investigation of this pulse sequence for brain metastatic evaluation is
warranted to determine its clinical utility.
High-resolution MRI also allowed us to quantify the number and
volume of metastases in the whole brain for every mouse in each model.
We found marked differences in tumor incidence, total tumor burden,
and appearance of metastases across the three models despite the fact they
are all meant to represent HER2+ brain metastatic breast cancer. The
mean volume of MDA-MB-231-BR-HER2 metastases at end point was
significantly larger than metastases in the JIMT-1-BR3 and
SUM190-BR3 models. It is important to also consider the end point
for each model to keep this result in context. The MDA-MB-231-BR-
HER2 model is the most aggressive; it grows many large tumors, despite
the least number of cells injected, and has a relatively short timeline with
end point typically required by day 36. In comparison, the JIMT-1-BR3
model has a lesser tumor burden and grows significantly smaller
metastases; yet end point is reached earlier at day 27/28. The
SUM190-BR3 model grows tumors similar in size to the JIMT-1-BR3
model; but the total tumor burden is small, and these animals can survive
more than twice as long to day 64.
In summary, the differences in appearance, number, volume, and
permeability across the three models highlight significant heteroge-
neity in HER2+ brain metastatic breast cancer. Our findings have
implications for both preclinical and clinical understanding of this
disease. It is important to study new diagnostics and therapeutics in
animal models that accurately reflect human disease, and the
heterogeneity presented here suggests that a panel of different models
may be necessary to adequately accomplish this. From a clinical
standpoint, understanding the heterogeneity presented in this workwill be important for improvements in detection strategies and
delivery of therapeutic agents. This work emphasizes the need for
personalized medicine; for example, if a patient has brain metastases
similar to the 231-BR-HER2 model, it could be assumed that MRI is
“blind” to approximately one third of the total brain metastatic
burden present in that patient and that systemic therapies may not be
effective against a large proportion of their disease; other treatment
avenues, such as radiotherapy, might be pursued in this case.
3D MRI is a powerful tool to provide an in vivo comprehensive
analysis of tumor incidence, tumor burden, and permeability status in
preclinical models of HER2+ brain metastatic breast cancer. This
information is challenging to obtain solely with ex vivomethods such as
histology and immunohistochemistry, but it is important for
understanding the natural heterogeneity present in experimental brain
metastasis models. Understanding the disease heterogeneity presented
here will be important for advancements in cancer diagnostics and
therapy and for improving patient management and survival.
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